← All trials
NCT03312699
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 19, 2017
- Primary completion
- Aug 31, 2022
- Completion date
- Aug 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Stanford UniversityLead sponsor
- Stanford UniversityReponsible party - principal investigator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Stanford UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.